インフォショップ ホームへ 株式会社グローバルインフォメーション
サイトマップ
その他のカテゴリ

月刊カタログ配信中

再生医療情報サイト regenerative-medicine.jp - 再生医療市場情報

医療/バイオの調査資料販 MEDINFO.JP

幹細胞特集
幹細胞特集ページ 幹細胞関連の
レポートをご紹介いたします。

バイオ医薬品企業による臨床ステージ別提携契約

Asia Antibody Congress 2008 公式サイト

Genomic Tools 公式サイト

BioProcess International 公式サイト

ACT 2008 公式サイト

BioProcess International  Asia Pacific 公式サイト

BioLOGIC India 2008 公式サイト

Antibody Engineering 2008 公式サイト
English Korean
【 英文市場調査報告書 】

プロテオミクス企業50社のプロファイル:競合する技術と新しい業界における企業提携

Kalorama's Proteomics 50: Competing Technologies and Alliances in an Emerging Industry

商品コード : 10401 Kalorama Information
出版日: 2001/11
発行 : Kalorama Information
電話でのお問い合わせ
価格情報
概要 原文目次
※この商品は英文にてご提供いたします。

With the Human Genome Project in its culminating phase, scientists are turning to the task of converting the soon to be completed DNA sequence into information that will improve human medicine and health care. One of the key challenges ahead is understanding how proteins direct biological functions. Proteomics, the science of the cellular protein universe, attempts to catalog and characterize proteins, compare variations in their expression levels under different conditions (i.e., various stages of disease compared with nondisease states), study their interactions, and identify their functional roles. However, these studies will not produce a complete "proteome," or a map of an organism, because cells are always changing, as is protein expression. Scientists believe there is a powerful distinction to be made between the molecular function of an isolated protein and the function of that protein in the complex cellular environment.

The goals of proteomics in medicine are to provide the ability to predict rather than confirm disease and to construct a new, systematic way to discover drugs. A preliminary step in achieving these goals requires that researchers acquire or invent the technology to fit its aspirations. Several approaches are being studied including structural genomics, a branch of proteomics, which studies the shapes of proteins with the goal of constructing a lexicon as well as an understanding of where in the body different proteins are produced, and how each is controlled. One molecular biologist, Richard Burgess of the McArdle Laboratory for Cancer Research at the University of Wisconsin, defines the scope of proteomics as "a grab bag of activities that are all in the postgenomics or functional genomics area, or the what-do-we-need-to-know-to-make-sense-of-all-the-genomics-data arena."

Proteomics is not the study of proteins one by one, as has been done traditionally, but in an automated, large-scale manner that requires new technologies and techniques. Proteomics includes not only the identification and quantification of proteins, but also the determination of their localization, modifications, interactions, activities, and, ultimately, their function. Considerable effort is currently being devoted to the development of novel technologies to unravel the mystery of proteins.

Companies competing in the proteomics space offer technology platforms for discovering or screening drug candidates or diagnostic markers. One of the ways emerging proteomics companies fund their enterprises, is selling their services to the pharmaceutical industry through an wide array of alliances and collaborations. This report will examine competing technologies, and the alliances being formed in the proteomics arena today.

Scope And Methodology

Although proteomics is being promoted as a separate industry, it is in fact a set of technologies, which are being increasingly used in combination with genomic technologies in the post-genomic era. This report provides an overview of the state-of- the-art of proteomics technologies, and profiles proteomics competitors. Companies competing in the proteomics sector offer platform technologies for discovering or screening drug candidates or diagnostic markers. One of the ways emerging proteomics companies fund their enterprises is by selling their services to the pharmaceutical industry through an array of alliances and collaborations. This report examines competing technologies, and the alliances being formed in the proteomics arena today.

Information in this report comes from both primary and secondary sources. An exhaustive search of online databases, scientific journals, investment reports, and company literature make up the secondary source material. Interviews with representatives of companies involved in proteomic research, academic institutions, research laboratories, professional associations, and government agencies make up the primary research. Data from all sources were compiled and analyzed in order to ascertain the best possible estimates of the market size and trends.

Key technologies discussed in depth include:

  • Protein Separation
  • Protein Identification and Characterization
  • Protein Chip Technology
  • Protein Function Studies

50 proteomic companies are profiled in this report, including:

  • Applied Biosystems
  • AxCell Biosciences
  • Cellomics
  • Cephergen Biosystems, Inc.
  • Dyax Corporation
  • GPC Biotech
  • Hybrigenics
  • InCyte Proteomics
  • Large Scale Proteomics Corporation
  • MDS Proteomics, Inc.
  • MediChem Life Sciences
  • Oxford GlycoSciences
  • Packard BioScience
  • Structural Bioinformatics
  • Syrrx

Chapter 1: Executive Summary

  • Scope and Methodology
  • Proteomics and Genomics
  • Proteomics and Bioinformatics
  • Challenges Facing Proteomics Research
    • The Magnitude and Complexity of the Task
    • Proteomics Data Are Increasing Exponentially
    • Technological Challenges
    • Increasing Need for Interdisciplinary Research Collaborations
  • Proteomics Technologies
    • Protein Separation
    • Mass Spectrometry
    • Protein Chip Technology
    • Protein Function Studies
    • Bioinformatics
  • Proteomics Technology Applications and Potential Markets
    • Proteomics In Perspective
    • Proteomics Technology Applications
  • Markets for Proteomics Technologies
  • Pharmaceutical Industry Trends
  • Healthcare Trends
  • Competitors in Proteomics
  • Funding Sources for Proteomics
    • Proteomics Startups Attract Venture Capital
    • Federal Funding for Proteomics Institutes and Research Centers

Chapter 2: Introduction

  • Biological Research in the Post-Genomic Era
  • Proteomics and Genomics
  • Proteomics and Bioinformatics
  • Challenges Facing Proteomics Research
    • The Magnitude and Complexity of the Task
    • Proteomics Data Are Increasing Exponentially
    • Technological Challenges
    • Increasing Need for Interdisciplinary Research Collaborations

Chapter 3: Proteomics Technologies

  • Overview
  • Principal Steps in Protein Analysis
    • Protein Separation
    • Protein Identification and Characterization
    • Protein Chip Technology
  • Protein Function Studies
    • Protein-Protein Interactions
    • Interaction Mapping and Analysis
  • Bioinformatics
    • Large Scale Databases

Chapter 4: Technology Applications And Potential Markets

  • Proteomics in Perspective
  • Proteomics Technology Applications
    • Basic Biological Research
    • Disease Markers For Diagnostics and Therapeutic Drug Discovery
    • Proteins as Biomarkers
    • Proteomics in Drug Discovery
  • Markets for Proteomics Technologies
    • Proteomics Technologies Market Value
    • Pharmaceutical Industry Trends
    • Healthcare Trends
  • Competitive Landscape
  • Funding Sources for Proteomics
    • Proteomics Startups Attract Venture Capital
    • Federal Funding for Proteomics Institutes and Research Centers

Chapter 5: Kalorama's Proteomics 50: Company Profiles

  • Activx Biosciences Inc.
  • AlphaGene Inc.
  • Applied Biosystems Group
  • Archemix Corporation
  • Athersys Incorporated
  • AxCell Biosciences Corporation
  • Beyond Genomics Incorporated
  • Biacore International AB
  • Caliper Technologies
  • Caprion Pharmaceuticals Inc.
  • Ciphergen Biosystems, Inc.
  • Compugen Ltd.
  • CuraGen Corporation
  • DoubleTwist Incorporated
  • Exelixis Incorporated
  • GPC Biotech AG
  • Geneva Bioinformatics SA (GeneBio)
  • GeneData Incorporated
  • GeneProt Incorporated
  • Genomic Solutions Incorporated
  • Hybrigenics SA
  • Incyte Genomics Incorporated
  • Inpharmatica Ltd
  • Integrative Proteomics, Inc.
  • Large Scale Biology Corporation
  • LigoCyte Pharmacuticals, Inc.
  • LumiCyte Incorporated
  • Lynx Therapeutics Incorporated
  • MDS Proteomics Incorporated
  • MediChem Life Sciences
  • Molecular Staging Incorporated
  • Myriad Genetics Incorporated
  • NeoGenesis Incorporated
  • Novalon Pharmaceutical Corporation
  • Odyssey Pharmaceuticals Incorporated
  • Oxford Glycosciences
  • Pepscan Systems
  • Phylos Incorporated
  • Protein Pathways Incorporated
  • Proteome Systems Limited
  • ProteoMetrics, Inc
  • Protiveris Incorporated
  • Rigel Pharmaceuticals Incorporated
  • Sense Proteomic Limited
  • SYNX Pharma Incorporated
  • Syrrx Incorporated
  • WITA Proteomics AG
  • Xencor Incorporated
  • Xerion Pharmaceuticals GmbH
  • Zyomyx Incorporated

Appendix--Company Index

List of Exhibits

Table 3-1: Top Protein Separation Technologies
Table 3-2: Top Protein Identification and Characterization Technologies
Table 3-3: Top Protein Chip Technology
Table 3-4: Top Technologies in Protein Function Studies
Table 3-5: Selected Databases Available for Proteomics Research
Table 4-1: Kalorama's Proteomics 50 in Collaborations with Pharmaceutical Companies
Figure 3-1: Proteomics Toolbox Technologies
Figure 4-1: Value of Proteomics Technologies, 2001-2006
    概要 原文目次
    ※この商品は英文にてご提供いたします。
    【 英文市場調査報告書 】
    プロテオミクス企業50社のプロファイル:競合する技術と新しい業界における企業提携
    Kalorama's Proteomics 50: Competing Technologies and Alliances in an Emerging Industry
    出版日: 2001/11
    電話でのお問い合わせ
    この商品について問い合わせる
    この商品のサンプル(抜粋)を依頼する
    価格

    ※ドル建て価格の商品のお支払いは、銀行レート (TTS: 110.89) 換算による円建てのご請求書にて承ります。

    US $ 1,497 換算 -> ¥ 166,002 (税抜) Hard Copy
    US $ 1,497 換算 -> ¥ 166,002 (税抜) PDF by E-mail
    US $ 1,747 換算 -> ¥ 193,724 (税抜) PDF by E-mail & Hard Copy
    US $ 2,994 換算 -> ¥ 332,004 (税抜) Global Site License
    商品コード : 10401
    関連する商品をキーワードで検索する